Prospector
Profile
218-04
|
| |
| Tapestry Pharmaceuticals, Inc. |
NAICS |
325412 |
| 4840 Pearl East Circle, Suite 300 W
Boulder, CO 80301 |
Description |
Pharmaceuticals Mfg. |
| (303) 516-8500 |
Employees |
31 |
| http://www.tapestrypharma.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
16.6500 |
| |
Assets |
(mil) |
24.6100 |
| |
Liability |
(mil) |
2.7000 |
| |
(for the year ended 2006-12-27) |
| |
|
Category:
Miscellaneous
|
| |
|
Event:
Tapestry Pharmaceuticals Inc. has effected a reduction in its operations and terminated its executives. The company has retained bankruptcy counsel and initiated steps to file for bankruptcy protection under Chapter 11 of the Bankruptcy Code and it does not anticipate paying any of these severance costs prior to filing. Grant Thornton LLP also notified Tapestry Pharmaceuticals, Inc. on Feb. 7, 2008, of the firm's resignation as the company's independent registered public accounting firm.
|
| |
|
Intellectual Property:
The Company owns or has licensed issued patents and has applied for patents relating to oncology programs. The Company has applied for and will continue to apply for patents covering its technologies, processes and products. The Company also relies on trade secrets and other proprietary information to develop and protect its competitive position, some of which is not patented. [SEC Filing 10-K 03-07-07]
|
| |
|
Description:
The Company, together with its subsidiaries, develops therapies for the treatment of cancer.
|
| |
|
Officers:
Leonard P. Shaykin (Chair & CEO); Patricia Pilia (EVP & Dir.); Gordon Link (SVP & CFO); Bruce W. Fiedler (VP & Controller); Stephen K. Carter, M.D. (Dir.); George Gould (Dir.); Elliot M. Maza (Dir.); Arthur H. Hayes, Jr., M.D. (Dir.); Robert E. Pollack, Ph.D. (Dir.); Richard N. Perle (Dir.)
|
| |
|
Auditor:
Grant Thornton LLP
|
| |
|
Securities:
Common Stock-Symbol TPPH; NasdaqCM;
16,629,861 common shares outstanding as of November 1, 2007.
|
| |
| |
| |
| return to main page |
